We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic to Debut AI-Powered Innovations at RSNA 2024: Stock to Gain?
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) is set to unveil groundbreaking technologies at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, to be held from Dec. 1-5. With a focus on enhancing breast health care, the company will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection.
Additionally, in the same event, Hologic will present the results of a recently published study demonstrating the performance of its Genius AI Detection 2.0 software across diverse patient populations.
Predicting HOLX Stock Movement Following the News
After the announcement on Nov. 25, HOLX shares edged up 0.6%, finishing at $79.44. The company continues to further its leading technologies to the next level through strong customer relationships, continuous improvement and the latest research, supporting healthcare providers in improving the patient experience and providing excellent care. Henceforth, we expect the recent development to boost market sentiment toward the HOLX stock.
Hologic currently has a market capitalization of $18.35 billion. The company’s earnings yield of 5.46% compares favorably to the industry’s yield of -5.73%. It delivered an earnings beat of 3.1%, on average, in the trailing four quarters.
More on Hologic’s Upcoming Presentations
For the first time, RSNA attendees will experience Hologic’s Envision Mammography Platform, which offers patients a high-speed Hologic 3D mammogram with an industry-leading 2.5-second scan time. The next-generation technology provides a more comfortable exam with tilt positioning, adapting to patients rather than the other way around. As the first FDA-approved mammography technology, the Envision platform enhances the detection of subtle objects, minimizes focal spot blur and improves 3D image sharpness.
Furthermore, Hologic will mark the U.S. debut of its next-generation Genius AI Detection PRO solution, which builds on its Genius AI Detection 2.0, and offers even greater accuracy and efficiency. It features a deep-learning 2D and 3D algorithm that improves specificity, an intuitive 1-10 case and lesion scoring and pre-populated exam reports, and an all-in-one interface that conveniently includes deep-learning breast density scoring along with key patient and mammogram quality information.
Image Source: Zacks Investment Research
Moreover, a study of more than 7,500 3D mammograms from women who identified as Asian, Black, Hispanic or White showed that the measured performance of Genius AI Detection 2.0 software was similar across all cohorts evaluated. This addresses the growing concern of reducing racial bias in AI algorithms in healthcare.
Other Developments in Hologic
Last month, the company signed a definitive agreement to acquire Gynesonics, Inc., a developer of minimally invasive solutions for women’s health. The latter’s Sonata System complements Hologic’s Surgical Solutions offering and also gives an expanded range of options for treating women suffering from heavy periods and fibroids.
Industry Prospects Favoring Hologic
Per a research report, the global AI in the Breast Imaging market was valued at $363.83 million in 2023 and is expected to grow at a compound annual rate of 28.9% by 2031. AI’s popularity in this industry has increased due to the creation of complex AI algorithms that can analyze huge amounts of imaging data.
HOLX Stock Price Performance
In the past six months, shares of Hologic have increased 9.7% against the industry’s fall of 0.3%.
Penumbra’s shares have risen 7.8% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 8.9% in the past year compared with the industry’s growth of 21.2%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Globus Medical’s 2024 earnings per share have increased 3.9% to $2.95 in the past 30 days. Shares of the company have surged 90.3% in the past year compared with the industry’s 15.1% rise. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic to Debut AI-Powered Innovations at RSNA 2024: Stock to Gain?
Hologic, Inc. (HOLX - Free Report) is set to unveil groundbreaking technologies at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago, to be held from Dec. 1-5. With a focus on enhancing breast health care, the company will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection.
Additionally, in the same event, Hologic will present the results of a recently published study demonstrating the performance of its Genius AI Detection 2.0 software across diverse patient populations.
Predicting HOLX Stock Movement Following the News
After the announcement on Nov. 25, HOLX shares edged up 0.6%, finishing at $79.44. The company continues to further its leading technologies to the next level through strong customer relationships, continuous improvement and the latest research, supporting healthcare providers in improving the patient experience and providing excellent care. Henceforth, we expect the recent development to boost market sentiment toward the HOLX stock.
Hologic currently has a market capitalization of $18.35 billion. The company’s earnings yield of 5.46% compares favorably to the industry’s yield of -5.73%. It delivered an earnings beat of 3.1%, on average, in the trailing four quarters.
More on Hologic’s Upcoming Presentations
For the first time, RSNA attendees will experience Hologic’s Envision Mammography Platform, which offers patients a high-speed Hologic 3D mammogram with an industry-leading 2.5-second scan time. The next-generation technology provides a more comfortable exam with tilt positioning, adapting to patients rather than the other way around. As the first FDA-approved mammography technology, the Envision platform enhances the detection of subtle objects, minimizes focal spot blur and improves 3D image sharpness.
Furthermore, Hologic will mark the U.S. debut of its next-generation Genius AI Detection PRO solution, which builds on its Genius AI Detection 2.0, and offers even greater accuracy and efficiency. It features a deep-learning 2D and 3D algorithm that improves specificity, an intuitive 1-10 case and lesion scoring and pre-populated exam reports, and an all-in-one interface that conveniently includes deep-learning breast density scoring along with key patient and mammogram quality information.
Image Source: Zacks Investment Research
Moreover, a study of more than 7,500 3D mammograms from women who identified as Asian, Black, Hispanic or White showed that the measured performance of Genius AI Detection 2.0 software was similar across all cohorts evaluated. This addresses the growing concern of reducing racial bias in AI algorithms in healthcare.
Other Developments in Hologic
Last month, the company signed a definitive agreement to acquire Gynesonics, Inc., a developer of minimally invasive solutions for women’s health. The latter’s Sonata System complements Hologic’s Surgical Solutions offering and also gives an expanded range of options for treating women suffering from heavy periods and fibroids.
Industry Prospects Favoring Hologic
Per a research report, the global AI in the Breast Imaging market was valued at $363.83 million in 2023 and is expected to grow at a compound annual rate of 28.9% by 2031. AI’s popularity in this industry has increased due to the creation of complex AI algorithms that can analyze huge amounts of imaging data.
HOLX Stock Price Performance
In the past six months, shares of Hologic have increased 9.7% against the industry’s fall of 0.3%.
HOLX’s Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Penumbra (PEN - Free Report) , Haemonetics (HAE - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s shares have risen 7.8% in the past year. Estimates for the company’s 2024 earnings per share have jumped 8.1% to $2.79 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics’ fiscal 2025 earnings per share have jumped 0.4% to $4.59 in the past 30 days. Shares of the company have rallied 8.9% in the past year compared with the industry’s growth of 21.2%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Globus Medical’s 2024 earnings per share have increased 3.9% to $2.95 in the past 30 days. Shares of the company have surged 90.3% in the past year compared with the industry’s 15.1% rise. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.65%. In the last reported quarter, it delivered an earnings surprise of 27.69%.